AVALON INVESTMENT & ADVISORY
Q2 2022 Form 13-F
HOUSTON, TEXAS
CIK 0001221362
· CRD 112556
· SEC-registered investment adviser
$3.5B Reported Value Total
AVALON ADVISORS LLC reports 5,107 total accounts under management (AUM). There are 4,505 discretionary accounts valued at $6,944,249,190, and 602 non-discretionary accounts valued at $1,437,465,551.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary & Non-Discretionary
Private funds (Form ADV)
20 funds
· $957.1M gross asset value
Other: $620.4M · Private Equity Fund: $333.0M · Hedge Fund: $3.7M
Source: Form ADV filed 2023-08-02
Reported value
$3.5B
Quarter over quarter
-13.7%
Holdings
309
Top-10 concentration
21.2%
Filing Structure
Reports holdings for
- CYNOSURE ADVISORS, LLC (not a 13F filer in our records) · File #028-18838 · Q4 2017 – Q2 2018 · declared by one filing
Holdings reported by
- Cynosure Management LLC · Q4 2018 – Q3 2022 · declared by one filing
- Segment Wealth Management LLC · Q3 2018 – Q2 2019 · declared by one filing
- CYNOSURE ADVISORS LLC (not a 13F filer in our records) · Q4 2017 – Q3 2018 · declared by one filing
Key People
Form ADV owners & control persons
Larry Triston Nakamura
CHIEF COMPLIANCE OFFICER
Thomas Allen Roupe
CHIEF EXECUTIVE OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q2 2022 13F record
Q2 2022 13F filing summary
| Period of report | June 30, 2022 |
|---|---|
| Filed | August 10, 2022 |
| Form | 13F-HR |
| Reported value | $3.5B |
| Positions | 309 |
| Change in reported value | -14.3% |
| New positions | 23 |
| Exited positions | 34 |
| Position turnover | 16.6% |
| Top-10 concentration | 21.2% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q1 2023 13F
Filed May 15, 2023
|
309 | $3.7B |
|
Q4 2022 13F
Filed Feb 13, 2023
|
314 | $3.5B |
|
Q3 2022 13F
Filed Nov 1, 2022
|
287 | $3.2B |
|
Q2 2022 13F
Filed Aug 10, 2022
|
309 | $3.5B |
|
Q1 2022 13F
Filed May 17, 2022
|
320 | $4.1B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
300 | $4.1B |
|
Q3 2021 13F
Filed Nov 8, 2021
|
335 | $4.3B |
|
Q2 2021 13F
Filed Jul 29, 2021
|
350 | $4.5B |
|
Q1 2021 13F
Filed May 13, 2021
|
341 | $4.4B |
|
Q4 2020 13F
Filed Feb 8, 2021
|
333 | $4.9B |
|
Q3 2020 13F
Filed Nov 4, 2020
|
322 | $4.5B |
|
Q2 2020 13F
Filed Aug 7, 2020
|
302 | $4.3B |
|
Q1 2020 13F
Filed May 5, 2020
|
301 | $3.9B |
|
Q4 2019 13F
Filed Feb 14, 2020
|
326 | $4.9B |
|
Q3 2019 13F
Filed Nov 14, 2019
|
305 | $4.5B |
|
Q2 2019 13F
Filed Aug 14, 2019
|
317 | $4.5B |
|
Q1 2019 13F
Filed Apr 24, 2019
|
330 | $4.4B |
|
Q4 2018 13F
Filed Feb 14, 2019
|
303 | $3.9B |
|
Q3 2018 13F
Filed Nov 14, 2018
|
344 | $3.6B |
|
Q2 2018 13F
Filed Aug 14, 2018
|
340 | $3.4B |
20 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | CVX Chevron Corp | $109.2M | 3.08% |
| 2 | AAPL Apple Inc | $97.8M | 2.76% |
| 3 | MSFT Microsoft Corp | $79.9M | 2.25% |
| 4 | MRK Merck & Co Inc | $70.9M | 2.0% |
| 5 | ABBV AbbVie Inc | $68.8M | 1.94% |
| 6 | TXN Texas Instruments Inc | $67.6M | 1.91% |
| 7 | GILD Gilead Sciences Inc | $67.6M | 1.91% |
| 8 | LRCX Lam Research Corp | $64.6M | 1.82% |
| 9 | UNH UnitedHealth Group Inc | $64.3M | 1.81% |
| 10 | CALM Cal Maine Foods Inc | $60.6M | 1.71% |
| 11 | PEP PepsiCo Inc | $60.1M | 1.69% |
| 12 | GOOGL Alphabet Inc | $57.7M | 1.63% |
| 13 | SPY S&P 500 SPDR ETF | $56.8M | 1.6% |
| 14 | CMI Cummins Inc | $55.8M | 1.57% |
| 15 | JPM JPMorgan Chase & Co | $55.3M | 1.56% |
| 16 | MS Morgan Stanley | $53.2M | 1.5% |
| 17 | WFC Wells Fargo Co | $51.8M | 1.46% |
| 18 | ACN Accenture PLC Ireland | $50.4M | 1.42% |
| 19 | BMY Bristol-Myers Squibb Co | $48.7M | 1.37% |
| 20 | CVS CVS Health Corp | $48.0M | 1.35% |
Values as reported on the Q2 2022 Form 13F. Every position is in the holdings table below.